Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

Cancer

Volumn 101, Issue 8, 2004, Pages 1835-1842

  Crump, Michael ^a,c   Baetz, Tara ^a   Couban, Stephen ^a   Belch, Andrew ^a   Marcellus, Deborah ^a   Howson Jan, Kang ^a   Imrie, Kevin ^a   Myers, Robert ^a   Adams, Grenfell ^a   Ding, Keyue ^a   Paul, Nancy ^a   Shepherd, Lois ^a   Iglesias, Jose ^b   Meyer, Ralph ^a  

^a Queen's Cancer Research Institute   (Canada)

^b ELI LILLY AND COMPANY   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Disease recurrence; Gemcitabine; Non Hodgkin lymphoma; Salvage chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANADA; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEATH; DIARRHEA; DYSPNEA; EDEMA; EMBOLISM; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LARGE CELL LYMPHOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MELENA; MOTOR NEUROPATHY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OTOTOXICITY; PETECHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PURPURA; RECURRENT CANCER; SENSORY NEUROPATHY; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DEXAMETHASONE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 4744361815     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20587     Document Type: Article

References (28)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
2. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood. 2000;96:2399-2404.
3. Girouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol. 1997;8:675-680.
4. Goss P, Shepherd F, Scott JG, Baker M, Sutton D, Sutcliffe S. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lymphoma. 1995;18:123-129.
5. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3776-3785.
6. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am. 1997;11:937-947.
7. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995;13:1734-1741.
8. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117-122.
9. Mollee P, Pereira D, Nagy T, et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant. 2002;30:273-278.
10. Drake M, Ranaghan L, Morris TC, et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol. 1997;98:745-749.
11. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999;17: 3786-3792.
12. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18:2603-2606.
13. Bergman AM, Ruiz van Haparen V, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521-530.
14. Csoka K, Liliemark J, Larsson R, Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol. 1995;22:47-53.
15. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:12-18.
16. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
17. von der MH, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
18. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
20. Cheson BD, Homing SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
21. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143-151.
22. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
23. Kantarjian H, Barlogie B, Plunkett W, et al. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol. 1983;1:689-694.
24. Rossof AH, Coltman CA Jr., Jones SE, Talley RW. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. Cancer Treat Rep. 1979;63:1605-1608.
25. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23:3-15.
26. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988;48:4024-4031.
27. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol. 1997;24:(2 Suppl 7):S7-2-S7-7.
28. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103:777-783.